<DOC>
	<DOCNO>NCT00646958</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability RX-1741 , oxazolidinone , versus linezolid , another oxazolidinone , treatment uncomplicated skin skin structure infection</brief_summary>
	<brief_title>Safety Efficacy Study Oxazolidinones Treat Uncomplicated Skin Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Skin Diseases , Bacterial</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Radezolid</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Adult patient uSSSI Adult ( men woman ) â‰¥18 year Females must postmenopausal least 1 year surgically sterile Sexually active male must use barrier method birth control 30 day study Acceptable clinical diagnosis uSSSI include , limited : Simple abscess , Impetiginous lesion , Folliculitis , Furunculosis , Carbuncles , Cellulitis The infection accompany 2 follow local sign symptom : Pain/tenderness , Swelling , Erythema , Localized warmth , Purulent drainage/discharge , Induration , Regional lymph node swell tenderness , Extension redness A sample microbiologic culture must obtain primary infection site screen visit The patient must require suitable candidate oral antibiotic therapy opinion Investigator able swallow tablet capsule intact A write , voluntarily sign informed consent must obtain patient prior initiation studyrelated procedure Cellulitis ( area great 10cm2 ) , chronic recurrent furunculosis , postoperative wound infection , leg ulcer , decubitus ulcer ( ) , erysipelas , progressive lymphangitis , acute paronychia deep tissue abscess pilonidal breast abscess . Also exclude skin infection result animal bite Patients complicate skin skin structure infection judge Investigator Infections treat surgical incision alone accord judgment Investigator Treatment follow antiinfective agent prior study drug administration : systemic antibiotic within 7 day ; azithromycin within 14 day ; longacting injectable antibiotic within 30 day Any infection require use concomitant antimicrobial agent , addition study drug Concomitant topical therapy infection site period within 48 hour prior study drug administration TOC A chronic underlying skin condition site infection infection involve prosthetic material A wound secondary burn injury acne vulgaris Any infection site require : intraoperative surgical debridement ; excision infect area Documented suspect bacteremia Fungal infection involve nail bed scalp primary uSSSI site Significant peripheral vascular disease An abscess anatomical location incidence anaerobic pathogen involvement increase Patient receive daily dose &gt; 15 mg systemic prednisone equivalent , &gt; 10 day within period start 14 day prior study drug administration anticipate TOC Patient know human immunodeficiency virus ( HIV ) infection . Medical history hypersensitivity allergic reaction linezolid accord judgment Investigator Patients receive serotonergic agent , selective serotonin reuptake inhibitor ( SSRIs ) , monoamine oxidase inhibitor ( MAOIs ) Patients severe liver disease History pheochromocytoma , untreated hyperthyroidism , untreated uncontrolled hypertension , carcinoid syndrome Evidence uncontrolled , clinically significant ( accord judgment Investigator ) cardiovascular , pulmonary , metabolic , gastrointestinal , neurological , endocrine disease ; malignancy psychiatric disorder Current evidence deep vein thrombosis superficial thrombophlebitis Experienced recent clinically significant coagulopathy Evidence clinically significant immunosuppression Patient previously enrol study Patient previously enrol clinical trial within 4 week enrollment TOC . Treatment investigational drug within 4 week prior study drug administration Patient reside chronic care facility Any underlying condition disease state would interfere completion study procedure evaluation absorption study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>